Plain-English translation of NCT07137494 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing MB-CART19.1, a new cellular therapy designed to treat central nervous system lymphoma (lymphoma in the brain and spinal fluid) that has come back or stopped responding to previous treatment. Researchers will take some of your immune cells, genetically modify them in the lab to fight the cancer, grow more of them, and then put the modified cells back into your body. The study will test different doses to find the safest and most effective amount.
Brain lymphoma that returns or doesn't respond to standard treatments is difficult to cure with conventional chemotherapy alone. This medication represents a new approach using the body's own immune system to target and destroy cancer cells specifically, which may offer hope to patients who have limited options.
You likely qualify if…
You likely don't qualify if…
First, you will have a procedure called leukapheresis, where blood is drawn from your body to collect immune cells, which are then sent to the laboratory for genetic modification and growth. While your cells are being prepared, you will receive chemotherapy to prepare your body. Once your modified cells are ready (usually 2–7 days after chemotherapy), they will be infused back into your body. After that, you will have regular blood draws and possibly spinal fluid samples to monitor how the treatment is working and watch for side effects.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States